James A Schoeneck
CIK 1420987 · Interim President · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$565
Companies
6
Total Filings
75
Lifetime Open-Market Net
-$1.79M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYNB | Director | — | $6.89 | — | $0 | 1 | 2026-06-17 |
| CLDI | Director | 5,260 | $0.11 | $565 | $150.0K | 2 | 2025-08-25 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | 40,817 | $9.75 | $398.0K | -$1.20M | 28 | 2025-07-02 |
| Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted | Director | 2,035,668 | $0.01 | $11.8K | $0 | 6 | 2024-10-15 |
| ANAB | Director | — | $53.02 | — | $0 | 2 | 2018-02-06 |
| Assertio Therapeutics, Inc (DEPO) Delisted | President and CEO | 495,105 | — | — | -$743.6K | 35 | 2017-02-10 |
Recent Filings · Page 5 of 8
75 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-10 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-07 | Assertio Therapeutics, Inc (DEPO) Delisted | Gift (G) | — | $0 | EDGAR |
| 2016-05-20 | Assertio Therapeutics, Inc (DEPO) Delisted | Gift (G) | −1,000 | $0 | EDGAR |
| 2016-03-21 | Assertio Therapeutics, Inc (DEPO) Delisted | Exer (M) | +30,483 | $120.1K | EDGAR |
| 2016-02-16 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-12-28 | Assertio Therapeutics, Inc (DEPO) Delisted | Exer (M) | +6,365 | $38.9K | EDGAR |
| 2015-12-15 | Assertio Therapeutics, Inc (DEPO) Delisted | Gift (G) | — | $0 | EDGAR |
| 2015-12-03 | Assertio Therapeutics, Inc (DEPO) Delisted | Tax (F) | −56,578 | -$1.07M | EDGAR |
| 2015-10-14 | Assertio Therapeutics, Inc (DEPO) Delisted | Gift (G) | — | $0 | EDGAR |
| 2015-09-29 | Assertio Therapeutics, Inc (DEPO) Delisted | Exer (M) | +63,561 | $408.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.